Zealand Pharma — Februar 2024
-
Her en interessant artikel med en række analytiker kommentar til dagens nyhed. Hvorfor lige præcis Survo måske har en fordel i MASH vs en række andre stoffer inkl wegovy. Men også en kommentar på at patienterne i forsøget ikke har været så syge som bla det studie LLY har lavet med Mounjaro
-
Weight-Loss Tizzy: Why One Stock Surged 27%, And Others Tumbled
Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss drug in MASH patients.
Investor's Business Daily (www.investors.com)
-
Kapitalfonden EQT har siden 2025 været aktionær i Zealand, jf. https://eqtgroup.com/current-portfolio/.
Jeg har forgæves søgt efter, hvor mange Zealand-aktier EQT ejer. -
Kjølstat, hvor ser du ZP tal i US ?
-
-
Jeg spiser nu lige brød til - men det ser positivt ud .-) Har ikke løbende fulgt denne notering.
-
Takker, gentogen

-
Godmorgen

-
Godmorgen - er der friske kursmål fra analytikere efter denne nyhed ?
-
Zealand Pharma: Ikke hverdagskost at C25 selskab stiger 35 %. Distancerer Lundbeck og AMBU på markedsværdier https://www.proinvestor.com/boards/118961
-
Zeal Announces Financial Results for the Full Year 2023 https://www.proinvestor.com/boards/118963
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind